Liquidia Corp current report, 09 January 2023

Full document

Business Context and Reporting Period

Liquidia Corporation filed a Form 8-K dated January 9, 2023, reporting that its wholly owned subsidiary, Liquidia Technologies, Inc., entered into a Revenue Interest Financing Agreement with HealthCare Royalty Partners IV, L.P. and HealthCare Royalty Management, LLC. The transaction is intended to support development and commercialization of YUTREPIA, an inhaled treprostinil product candidate for pulmonary hypertension.

Key Financial Terms and Liquidity

  • The investor agreed to provide up to $100.0 million, subject to customary closing conditions and specified funding triggers.
  • $32.5 million was scheduled for the initial closing, expected approximately 15 business days after January 9, 2023.
  • Additional potential funding consists of $7.5 million for qualifying pulmonary hypertension product rights, $35.0 million upon the earlier of YUTREPIA regulatory approval or a favorable patent-litigation determination, and $25.0 million subject to mutual agreement.
  • Approximately $22.3 million of the initial funding was expected to repay and retire the company group’s Silicon Valley Bank loan.
  • In exchange, the company will pay tiered royalties on annual net revenue after YUTREPIA’s first commercial sale. Rates range from 3.60% to 10.00% on the first $250 million of annual net revenue, 1.44% to 4.00% on the next $250 million, and 0.36% to 1.00% above $500 million.
  • The agreement also requires fixed quarterly payments, potential additional payments if first commercial sale does not occur by June 30, 2025, and minimum quarterly royalty payments beginning in 2026.
  • The investor’s return is generally capped at 175% of the funded investment, subject to an additional payment needed to produce an 18% internal rate of return.
  • The company group must maintain cash and cash equivalents of at least $7.5 million during 2024 and at least $15.0 million from January 1, 2025 onward.
  • The obligations are secured by first-priority perfected security interests in substantially all assets of the company group, subject to limited exceptions.

Material Changes Versus the Prior Comparable Period

  • The filing does not present comparative revenue, earnings, cash flow, margins, or balance-sheet results.
  • The transaction creates a new revenue-based financing obligation and provides potential liquidity of up to $100.0 million.
  • The Silicon Valley Bank loan was to be fully repaid at the initial closing, subject to completion of the transaction.

Guidance, Outlook, Risks, and Unusual Items

  • The stated revenue thresholds are contractual royalty tiers and are expressly not financial guidance or projections.
  • Future funding depends on specified events, including product-rights acquisitions, YUTREPIA approval or a favorable patent decision, and mutual agreement for the final tranche.
  • If YUTREPIA’s first commercial sale does not occur by June 30, 2025, additional payments may be required. Minimum payment obligations also apply if the investor has not received 60% of funded amounts by December 31, 2026, or 100% by December 31, 2028.
  • The investor may accelerate payments following a change of control or event of default. Certain material adverse events or breaches may also permit termination and repayment.
  • If the FDA approves a therapeutically equivalent inhaled treprostinil product before the investor has received 100% of funded amounts, additional repayment may be required.
  • The agreement includes customary covenants, representations, information rights, indemnification provisions, cross-defaults, and insolvency-related events of default.

Investor Verification Checklist

  • Confirm whether the initial $32.5 million funding closed and verify the exact amount used to retire the Silicon Valley Bank loan.
  • Review the complete financing agreement, including royalty-rate determination, payment schedules, security interests, covenants, and default provisions.
  • Track YUTREPIA’s FDA approval status, patent litigation outcome, and commercial-launch timing.
  • Assess compliance with the $7.5 million and $15.0 million minimum cash covenants.
  • Review subsequent filings for additional funding, changes in the financing obligation, and any required minimum or accelerated payments.
  • The filing does not provide current revenue, profitability, cash flow, debt balances after closing, or liquidity beyond the stated transaction terms.